Vol 51(2017) N 2 p. 216-225; DOI 10.1134/S0026893317010150
N.M. Ratnikova1,2, Y.N. Lezhnin1,2, E.I. Frolova1, J.E. Kravchenko1,2, S.P. Chumakov1,2*
CD47 receptor as a primary target for cancer therapy1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia
2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
Received - 2015-12-22; Accepted - 2016-07-04
Recently, a number of new highly efficient antibody-based anticancer therapeutics have emerged. These receptor-binding antibodies have beneficial toxicity profiles associated with relatively mild side effects. Therefore, the search for novel surface proteins that are present on cancer cells and play important metabolic or defensive roles has intensified. Additionally, the therapeutic stimulation of patient's immune system in order to aim its components, specifically, phagocytes and cytotoxic T-lymphocytes, at tumor cells is gaining traction. This review is focused on the CD47 surface receptor, a ubiquitously expressed molecule, which could nevertheless serve as a therapeutic target due to its ability to simultaneously stimulate both natural and adaptive immune response.
CD47, therapeutic antibodies, SIRPα, immunotherapy, cancer stem cells